Biopharma Manufacturing, Scale-Up & Commercial Readiness

PharmaXcelerate USA 2026 brings together senior manufacturing leaders, engineers, and decision-makers from the biopharma and biotech industries to address one central challenge: how to successfully scale complex therapies into commercial reality. Taking place on 15–16 September 2026 in Philadelphia, this edition focuses on manufacturing scale-up, facility strategy, and operational readiness.

Across two days, delegates will engage with experts from leading organizations including AstraZeneca, Pfizer, Biogen, Moderna, Takeda, CSL Behring, and Eli Lilly, alongside engineering, quality, and manufacturing leaders shaping the future of biopharma production. The agenda is built around real-world case studies and operational insights, covering critical topics such as multi-modality facility design, Annex 1 compliance and contamination control, scaling biologics and advanced therapies, MS&T transformation, and the integration of AI, digital twins, and data-driven manufacturing systems. 

The program is designed to go beyond theory, focusing on what actually determines success at scale. Sessions explore how manufacturers are overcoming bottlenecks in tech transfer, managing multi-site and CMO networks, implementing predictive manufacturing through PAT and data science, and transitioning from reactive compliance to adaptive quality systems.

PharmaXcelerate USA is a focused, senior-level forum for professionals responsible for manufacturing strategy, facility design, process development, and operational performance. Join your peers in Philadelphia to exchange lessons learned, benchmark approaches, and explore the strategies and technologies defining the future of biopharma manufacturing in the US.